ClinicalTrials.gg
TerminatedNCT01773187Updated Sep 29, 2020Results posted

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

A Phase 3 interventional study of Pacritinib and Best Available Therapy in Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, sponsored by CTI BioPharma. Terminated at 81 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
2nd of 18
327 · median 35
Started
2013
the only one that year
Phase 3
3 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
5 of 18
CTI BioPharma

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 3rd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.

Read the detailed description

Multicenter, randomized, controlled, phase 3 trial comparing the safety and efficacy of pacritinib with that of BAT in patients with primary or secondary myelofibrosis. Approximately 322 eligible patients will be randomized in a 2:1 allocation to pacritinib (400mg QD) or BAT (includes any physician-selected treatment for myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)). Spleen volume will be measured by MRI or CT at baseline and every 12 weeks thereafter. An independent radiology facility (IRF), blind to treatment assignments, will measure spleen volumes. Patients will also be followed for safety, Leukemia Free Survival (LFS), Overall Survival (OS), frequency of red blood cell (RBC) and platelet transfusions, and other exploratory endpoints. An Independent Data Monitoring Committee (IDMC) will evaluate the safety of pacritinib.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Keywords

  • Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
  • Primary Myelofibrosis
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Bone Marrow Disease
  • Hematologic Disease
  • Splenomegaly
  • Pacritinib
  • MPN-SAF
  • MPN-SAF TSS
  • Anemia
  • Myeloproliferative Neoplasm
  • Spleen volume
  • Thrombocytopenia
  • SB1518
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intermediate -1 or -2 or high-risk Myelofibrosis (per Passamonti et al 2010)
  • Palpable splenomegaly ≥ 5 cm on physical examination
  • Total Symptom Score >13 on the MPN-SAF TSS 2.0, not including the inactivity question
  • Patients who are or red blood cell transfusion-dependent are eligible
  • Adequate white blood cell counts (with low blast counts), liver function, and renal function
  • No spleen radiation therapy for 6-12 months
  • Last therapy for myelofibrosis was 2-4 weeks ago, including any erythropoietic or thrombopoietic agent
  • Not pregnant, not lactating, and agree to use effective

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a JAK2 inhibitor
  • History of (or plans to undergo) spleen removal surgery or stem cell transplant
  • Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory bowel disease, chronic diarrhea, or constipation
  • Cardiovascular disease, including recent history or currently clinically symptomatic and uncontrolled: congestive heart failure, arrhythmia, angina, prolongation or other QTc risk factors, myocardial infarction
  • Other within last 3 years other than certain limited skin, cervical, prostate, breast, or bladder cancers
  • Other ongoing, uncontrolled illnesses (including infection and active hepatitis A, B, or C), psychiatric disorder, or social situation that would prevent good care on this study
  • \< 6 months
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Pacritinib

    Pacritinib 400 mg QD

    Drug: Pacritinib

  • Active comparator
    Best Available Therapy

    BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)

    Drug: Best Available Therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Spleen Volume Reduction

    Number of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Total Symptom Score (TSS) Reduction

    Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

    Time frame: Baseline to Week 24

07

Results

Posted Sep 29, 2020

Participant flow

Participant flow — Overall Study
MilestonePacritinibBest Available Therapy
Started220107
Completed16775
Not completed5332

Outcome measures

PrimarySpleen Volume Reduction

Number of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Spleen Volume Reduction
ParticipantsPacritinibBest Available Therapy
Spleen Volume Reduction425
Statistical analysis
  • Pacritinib vs Best Available Therapy · Fisher Exact · p = 0.0003
SecondaryTotal Symptom Score (TSS) Reduction

Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Total Symptom Score (TSS) Reduction
ParticipantsPacritinibBest Available Therapy
Total Symptom Score (TSS) Reduction195
Statistical analysis
  • Pacritinib vs Best Available Therapy · Fisher Exact · p = 0.2368

Adverse events

Collected over Time of signing informed consent through 30 days after the last study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pacritinib27/220 (12.3%)117/220 (53.2%)207/220 (94.1%)
Best Available Therapy3/106 (2.8%)33/106 (31.1%)81/106 (76.4%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPacritinibBest Available Therapy
AnemiaBlood and lymphatic system disorders16/2205/106
PneumoniaInfections and infestations16/2204/106
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2204/106
Cardiac FailureCardiac disorders7/2203/106
Disease ProgressionGeneral disorders6/2203/106
PyrexiaGeneral disorders6/2203/106
Basal cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/2202/106
EpistaxisRespiratory, thoracic and mediastinal disorders5/2200/106
DiarrhoeaGastrointestinal disorders4/2202/106
SepisInfections and infestations2/2202/106
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPacritinibBest Available Therapy
DiarrhoeaGastrointestinal disorders142/22014/106
NauseaGastrointestinal disorders70/2207/106
AnaemiaBlood and lymphatic system disorders58/22018/106
ThrombocytopeniaBlood and lymphatic system disorders48/22015/106
VomitingGastrointestinal disorders46/2207/106
Oedema peripheralGeneral disorders24/22016/106
FatigueGeneral disorders33/2209/106
Abdominal painGastrointestinal disorders29/22011/106
PyrexiaGeneral disorders17/22011/106
ConstipationGastrointestinal disorders22/2208/106

Baseline characteristics

Represents Intent To Treat population (number of randomized patients)

Age, Categorical
Age, Categorical(Participants)PacritinibBest Available TherapyTotal
<=18 years000
Between 18 and 65 years8552137
>=65 years13555190
Age, Continuous
Age, Continuous(years)PacritinibBest Available TherapyTotal
Mean65.5 ± 10.8564.8 ± 9.1265.3 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)PacritinibBest Available TherapyTotal
Female9547142
Male12560185
Region of Enrollment
Region of Enrollment(participants)PacritinibBest Available TherapyTotal
New Zealand16420
Netherlands13821
Belgium819
Hungary492170
Czechia9918
United States325
Italy111021
United Kingdom19625
Australia291746
France26935
Germany224
Russia351853
08

Study locations

81 sites
  • CTI Investigational Site 10002
    Scottsdale, Arizona 85259, United States
  • CTI Investigational Site 10004
    Omaha, Nebraska 68198, United States
  • CTI Investigational Site 10001
    Morristown, New Jersey 07962, United States
  • CTI Investigational Site 10003
    Greenville, South Carolina 29601, United States
  • CTI Investigational Site 61006
    Box Hill, Australia
  • CTI Investigational Site 61001
    Coffs Harbour, Australia
  • CTI Investigational Site 61005
    Geelong, Australia
  • CTI Investigational Site 61003
    Gosford, Australia
  • CTI Investigational Site 61004
    Hobart, Australia
  • CTI Investigational Site 61002
    Milton, Australia
  • CTI Investigational Site 32002
    Antwerp, Belgium
  • CTI Investigational Site 32003
    Antwerp, Belgium
  • CTI Investigational Site 32001
    Brugge, Belgium
  • CTI Investigational Site 32005
    Bruxelles, Belgium
  • CTI Investigational Site 32004
    La Louviere, Belgium
  • CTI Investigational Site 42003
    Brno, Czechia
  • CTI Investigational Site 42001
    Olomouc, Czechia
  • CTI Investigational Site 42002
    Plzen, Czechia
  • CTI Investigational Site 42004
    Prague, Czechia
  • CTI Investigational Site 33005
    Amiens, France
  • CTI Investigational Site 33006
    Caen, France
  • CTI Investigational Site 33011
    Grenoble, France
  • CTI Investigational Site 33012
    Lens, France
  • CTI Investigational Site 33007
    Lille, France
  • CTI Investigational Site 33001
    Nimes Cedex, France
  • CTI Investigational Site 33004
    Paris, France
  • CTI Investigational Site 33008
    Paris, France
  • CTI Investigational Site 33009
    Pessac, France
  • CTI Investigational Site 33010
    Pierre Benite, France
  • CTI Investigational Site 33003
    Strasbourg, France
  • CTI Investigational Site 33002
    Toulouse, France
  • CTI Investigational Site 49006
    Berlin, Germany
  • CTI Investigational Site 49007
    Berlin, Germany
  • CTI Investigational Site 49003
    Dresden, Germany
  • CTI Investigational Site 49008
    Essen, Germany
  • CTI Investigational Site 49002
    Freiburg, Germany
  • CTI Investigational Site 49001
    Koln, Germany
  • CTI Investigational Site 49005
    Mainz, Germany
  • CTI Investigational Site 49004
    Munchen, Germany
  • CTI Investigational Site 49009
    Munster, Germany
  • CTI Investigational Site 36002
    Budapest, Hungary
  • CTI Investigational Site 36005
    Debrecen, Hungary
  • CTI Investigational Site 36006
    Gyula, Hungary
  • CTI Investigational Site 36003
    Kaposvar, Hungary
  • CTI Investigational Site 36004
    Kecskemet, Hungary
  • CTI Investigational Site 36001
    Szeged, Hungary
  • CTI Investigational Site 36008
    Szolnok, Hungary
  • CTI Investigational Site 36007
    Szombathely, Hungary
  • CTI Investigational Site 39003
    Bologna, Italy
  • CTI Investigational Site 39001
    Firenze, Italy
  • CTI Investigational Site 39005
    Milano, Italy
  • CTI Investigational Site 39004
    Monza, Italy
  • CTI Investigational Site 39002
    Padova, Italy
  • CTI Investigational Site 39008
    Reggio Emilia, Italy
  • CTI Investigational Site 39006
    Rimini, Italy
  • CTI Investigational Site 31001
    Amsterdam, Netherlands
  • CTI Investigational Site 31002
    Maastricht, Netherlands
  • CTI Investigational Site 31003
    Rotterdam, Netherlands
  • CTI Investigational Site 31004
    Utrecht, Netherlands
  • CTI Investigational Site 64001
    Christchurch, New Zealand
  • CTI Investigational Site 64004
    Dunedin, New Zealand
  • CTI Investigational Site 64002
    Hamilton, New Zealand
  • CTI Investigational Site 64003
    Takapuna, New Zealand
  • CTI Investigational Site 70011
    Izhevsk, Russian Federation
  • CTI Investigational Site 70008
    Moscow, Russian Federation
  • CTI Investigational Site 70009
    Moscow, Russian Federation
  • CTI Investigational Site 70002
    Petrozavodsk, Russian Federation
  • CTI Investigational Site 70010
    Saint Petersburg, Russian Federation
  • CTI Investigational Site 70005
    Samara, Russian Federation
  • CTI Investigational Site 70006
    Sochi, Russian Federation
  • CTI Investigational Site 70001
    St. Petersburg, Russian Federation
  • CTI Investigational Site 70004
    St. Petersburg, Russian Federation
  • CTI Investigational Site 70007
    Volgograd, Russian Federation
  • CTI Investigational Site 44004
    Birmingham, United Kingdom
  • CTI Investigational Site 44008
    Bournemouth, United Kingdom
  • CTI Investigational Site 44002
    Cambridge, United Kingdom
  • CTI Investigational Site 44003
    Cardiff, United Kingdom
  • CTI Investigational Site 44001
    London, United Kingdom
  • CTI Investigational Site 44007
    London, United Kingdom
  • CTI Investigational Site 44006
    Manchester, United Kingdom
  • CTI Investigational Site 44005
    Oxford, United Kingdom
09

References and documents

Publications

  • Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. PubMed 28336242 ↗
  • Tremblay D, Mesa R, Scott B, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv. 2020 Dec 8;4(23):5929-5935. doi: 10.1182/bloodadvances.2020002970. PubMed 33275766 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Jan 2015, 24 months.

Results were first posted in Sep 2020, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2013
First posted
Jan 23, 2013
StartActual
Jan 2013
Primary completionActual
Jan 2015
CompletionActual
Apr 2016
Results first posted
Sep 29, 2020
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01773187
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
Jan 23, 2013
Start date
Jan 2013
Primary completion
Jan 2015
Completion
Apr 2016
Results posted
Sep 29, 2020
Last update
Sep 29, 2020

Study contacts

Beth Ziemba
study director · VP, Pharmacovigilance, Clinical Operations, QA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion